Report Detail
Advanced Cancer Pain Management(ACPM) - Market Insights, Epidemiology and Market Forecast-2028
- RnM3869815 |
- 24 January, 2020 |
- Global |
- 142 Pages |
- DelveInsight |
- Other
DelveInsight’s ‘Advanced Cancer Pain Management(ACPM) - Market Insights, Epidemiology and Market Forecast-2028 report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of ACPMs in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Advanced Cancer Pain Management (ACPM) from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Geography Covered
• The United States
• EU5 (Germany, France, Italy, Spain and the United Kingdom)
• Japan
Study Period: 2017-2028
Advanced Cancer Pain Management (ACPM) - Disease Understanding and Treatment Algorithm
Pain is the commonest symptom of cancer at diagnosis and rises in prevalence throughout and beyond cancer treatment and continues to be a major source of suffering in advanced cancer with adverse effects on patients’ life quality and caregiver distress. This includes different types of pain such as neuropathic, incident or breakthrough, and bone pain associated with poor pain control and with a negative impact on physical, cognitive, and social functioning and mood.
The DelveInsight Advanced Cancer Pain Management (ACPM) market report gives the thorough understanding of the Advanced Cancer Pain Management by including details such as disease definition, classification, symptoms, etiology, pathophysiology and clinical assessment. It also provides treatment algorithms and treatment guidelines for Advanced Cancer Pain Management in the US and Europe.
Advanced Cancer Pain Management Epidemiology
The Advanced Cancer Pain Management (ACPM) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Incident Cases of Advanced Stage Cancers, Incidence of Cancer Pain based on Etiologies, Incidence of Chemotherapy Induced Peripheral Neuropathy, Severity Based Incidence of Cancer Pain, Total Incidence of Cancer Pain based on Pathophysiology, Incidence of Cancer Pain based on Temporal Variations, Incidence of Breakthrough Pain, Incidence of Cancer Pain based on duration) scenario of Advanced Cancer Pain Management (ACPM) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2028.
According to DelveInsight, the total number of Incident cases of Advanced Cancer Pain Management (ACPM) in 7 MM was found to be 1,537,681, in the year 2017.
Advanced Cancer Pain Management Drug Chapters
This segment of the Advanced Cancer Pain Management report encloses the detailed analysis of late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Opioid based treatments are the mainstay of moderate-to-severe cancer-related pain. The goal of long-term opioid treatment is to provide sustained, clinically meaningful relief of pain with side effects that are tolerable and an overall benefit to quality of life.
Advanced Cancer Pain Management Market Outlook
The Advanced Cancer Pain Management market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the market of Advanced Cancer Pain Management in 7MM was found to be USD 871.50 Million in 2017, and is expected to increase during the course of the study period (2017-2028). Among the 7MM, the United States accounts for the largest market size of Acute Bacterial Prostatitis, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.
Advanced Cancer Pain Management Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Advanced Cancer Pain Management Report Insights
• Patient Population
• Therapeutic Approaches
• Pipeline Analysis
• Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies
Key strengths
• 9 Years Forecast
• 7MM Coverage
• Epidemiology Segmentation
• Key Cross Competition
• Market Size by Therapies
• Drugs Uptake
Key assessments
• Pipeline Product Profiles
• Key Products and Key Players
• Market Drivers and Barriers
Key Benefits
• This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Advanced Cancer Pain Management market
• Organize sales and marketing efforts by identifying the best opportunities for Advanced Cancer Pain Management market
• To understand the future market competition in the Advanced Cancer Pain Management market.
1. Key Insights
2. Advanced Cancer Pain Management Market Overview at a Glance
- 2.1. Market Share (%) of Advanced Cancer Pain Management in 2017 – 7MM
- 2.2. Market Share (%) of Advanced Cancer Pain Management in 2028 – 7MM
3. Disease Background and Overview
- 3.1. Introduction
- 3.2. Etiology and types
- 3.3. Cancer Pain Classification Systems
- 3.3.1. International Association for the Study of Pain (IASP) Taxonomy
- 3.3.2. ICD-11
- 3.3.3. Edmonton Classification System for Cancer Pain (ECS-CP)
- 3.4. Cancer Pain Pathophysiology
- 3.5. Cancer Pain Syndromes
- 3.6. Clinical Presentation and Assessment of Pain
4. Epidemiology and Patient Population
- 4.1. Key Findings
- 4.2. Incidence of Cancer Pain based on Etiologies in 7MM
- 4.3. Assumptions and Rationale: 7MM
- 4.4. Forecast Parameters
5. Country Wise-Epidemiology
- 5.1. The United States
- 5.1.1. Total Incident Cases of Advanced Stage Cancers in the United States
- 5.1.2. Incidence of Cancer Pain based on Etiologies in the United States
- 5.1.3. Incidence of Chemotherapy Induced Peripheral Neuropathy (CIPN) in the United States
- 5.1.4. Severity Based Incidence of Cancer Pain on in the United States
- 5.1.5. Total Incidence of Cancer Pain based on Pathophysiology in the United States
- 5.1.6. Incidence of Cancer Pain based on Temporal Variations in the United States
- 5.1.7. Incidence of Breakthrough Pain in the United States
- 5.1.8. Incidence of Cancer Pain based on duration in the United States
- 5.2. EU-5
- 5.3. Germany
- 5.3.1. Total Incident Cases of Advanced Stage Cancers in Germany
- 5.3.2. Incidence of Cancer Pain based on Etiologies in Germany
- 5.3.3. Incidence of Chemotherapy Induced Peripheral Neuropathy (CIPN) in Germany
- 5.3.4. Severity Based Incidence of Cancer Pain on in Germany
- 5.3.5. Total Incidence of Cancer Pain based on Pathophysiology in Germany
- 5.3.6. Incidence of Cancer Pain based on Temporal Variations in Germany
- 5.3.7. Incidence of Breakthrough Pain in Germany
- 5.3.8. Incidence of Cancer Pain based on duration in Germany
- 5.4. France
- 5.4.1. Total Incident Cases of Advanced Stage Cancers in France
- 5.4.2. Incidence of Cancer Pain based on Etiologies in France
- 5.4.3. Incidence of Chemotherapy Induced Peripheral Neuropathy (CIPN) in France
- 5.4.4. Severity Based Incidence of Cancer Pain on in France
- 5.4.5. Total Incidence of Cancer Pain based on Pathophysiology in France
- 5.4.6. Incidence of Cancer Pain based on Temporal Variations in France
- 5.4.7. Incidence of Breakthrough Pain in France
- 5.4.8. Incidence of Cancer Pain based on duration in France
- 5.5. Italy
- 5.5.1. Total Incident Cases of Advanced Stage Cancers in Italy
- 5.5.2. Incidence of Cancer Pain based on Etiologies in Italy
- 5.5.3. Incidence of Chemotherapy Induced Peripheral Neuropathy (CIPN) in Italy
- 5.5.4. Severity Based Incidence of Cancer Pain on in Italy
- 5.5.5. Total Incidence of Cancer Pain based on Pathophysiology in Italy
- 5.5.6. Incidence of Cancer Pain based on Temporal Variations in Italy
- 5.5.7. Incidence of Breakthrough Pain in Italy
- 5.5.8. Incidence of Cancer Pain based on duration in Italy
- 5.6. Spain
- 5.6.1. Total Incident Cases of Advanced Stage Cancers in Spain
- 5.6.2. Incidence of Cancer Pain based on Etiologies in Spain
- 5.6.3. Incidence of Chemotherapy Induced Peripheral Neuropathy (CIPN) in Spain
- 5.6.4. Severity Based Incidence of Cancer Pain on in Spain
- 5.6.5. Total Incidence of Cancer Pain based on Pathophysiology in Spain
- 5.6.6. Incidence of Cancer Pain based on Temporal Variations in Spain
- 5.6.7. Incidence of Breakthrough Pain in Spain
- 5.6.8. Incidence of Cancer Pain based on duration in Spain
- 5.7. United Kingdom
- 5.7.1. Total Incident Cases of Advanced Stage Cancers in United Kingdom
- 5.7.2. Incidence of Cancer Pain based on Etiologies in United Kingdom
- 5.7.3. Incidence of Chemotherapy Induced Peripheral Neuropathy (CIPN) in United Kingdom
- 5.7.4. Severity Based Incidence of Cancer Pain on in United Kingdom
- 5.7.5. Total Incidence of Cancer Pain based on Pathophysiology in United Kingdom
- 5.7.6. Incidence of Cancer Pain based on Temporal Variations in United Kingdom
- 5.7.7. Incidence of Breakthrough Pain in United Kingdom
- 5.7.8. Incidence of Cancer Pain based on duration in United Kingdom
- 5.8. Japan
- 5.8.1. Total Incident Cases of Advanced Stage Cancers in Japan
- 5.8.2. Incidence of Cancer Pain based on Etiologies in Japan
- 5.8.3. Incidence of Chemotherapy Induced Peripheral Neuropathy (CIPN) in Japan
- 5.8.4. Severity Based Incidence of Cancer Pain on in Japan
- 5.8.5. Total Incidence of Cancer Pain based on Pathophysiology in Japan
- 5.8.6. Incidence of Cancer Pain based on Temporal Variations in Japan
- 5.8.7. Incidence of Breakthrough Pain in Japan
- 5.8.8. Incidence of Cancer Pain based on duration in Japan
6. Treatment and Management
- 6.1. NCCN Guidelines
- 6.2. ESMO Clinical Practice Guidelines
- 6.3. Spanish Guidelines
- 6.4. Multimodal Personalized Management of Cancer Pain
- 6.5. Patient Journey
- 6.6. The Role of Cannabinoids In Cancer Pain Management
7. Unmet Needs
8. Case Studies
- 8.1. Case Studies in Pain Management: Cancer Pain
- 8.2. Cancer–related visceral pain
- 8.3. Complex Pain Management: Case study
9. Emerging drugs
- 9.1. PPP011: Tetra Bio-Pharma Inc.
- 9.1.1. Product Description
- 9.1.2. Product Development Activities
- 9.1.3. Clinical development
- 9.1.3.1. Clinical Trials Information
- 9.1.4. Product Profile
- 9.2. Halneuron: Wex Pharma
- 9.2.1. Product Description
- 9.2.2. Product Development Activities
- 9.2.3. Clinical development
- 9.2.3.1. Clinical Trials Information
- 9.2.4. Safety and Efficacy
- 9.2.5. Product Profile
- 9.3. Tanezumab: Pfizer
- 9.3.1. Product Description
- 9.3.2. Product Development Activities
- 9.3.3. Clinical development
- 9.3.3.1. Clinical Trials Information
- 9.3.4. Product Profile
10. Other Product of interest
- 10.1. Tetrodotoxin: Wex Pharma
- 10.1.1. Product Description
- 10.1.2. Clinical development
- 10.1.2.1. Clinical Trials Information
- 10.1.3. Safety and Efficacy
- 10.1.4. Product Profile
- 10.2. Sativex: GW Pharmaceuticals
- 10.2.1. Product Description
- 10.2.2. Product Development Activities
- 10.2.3. Clinical development
- 10.2.3.1. Clinical Trials Information
- 10.2.4. Safety and Efficacy
- 10.2.5. Product Profile
- 10.3. NPC-06: Nobelpharma
- 10.3.1. Product Description
- 10.3.2. Product Development Activities
- 10.3.3. Clinical development
- 10.3.3.1. Clinical Trials Information
- 10.3.4. Product Profile
11. Advanced Cancer Pain Management: 7 Major Market Analysis
- 11.1. Key Findings
- 11.2. Market Size of Advanced Cancer Pain Management in 7MM
- 11.3. Market Outlook: 7MM
- 11.4. Forecast Parameters
- 11.5. United States Market Size
- 11.5.1. Total Market size of Advanced Cancer Pain Management
- 11.5.2. Market Size by Therapies
12. EU-5 Countries: Market Size
- 12.1. Germany
- 12.1.1. Total Market size of Advanced Cancer Pain Management in Germany
- 12.1.2. Market Size by Therapies
- 12.2. France
- 12.2.1. Total Market Size of Advanced Cancer Pain Management
- 12.2.2. Market Size by Therapies
- 12.3. Italy
- 12.3.1. Total Market Size of Advanced Cancer Pain Management
- 12.3.2. Market Size by Therapies
- 12.4. Spain
- 12.4.1. Total Market Size of Advanced Cancer Pain Management
- 12.4.2. Market Size by Therapies
- 12.5. The United Kingdom
- 12.5.1. Total Market Size of Advanced Cancer Pain Management
- 12.5.2. Market Size by Therapies
13. Japan: Market Size
- 13.1. Japan Market Size
- 13.1.1. Total Market Size of Advanced Cancer Pain Management
- 13.1.2. Market Size by Therapies
14. Market Drivers
15. Market Barriers
16. Appendix
- 16.1. Bibliography
- 16.2. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight
Summary:
Get latest Market Research Reports on Advanced Cancer Pain Management(ACPM). Industry analysis & Market Report on Advanced Cancer Pain Management(ACPM) is a syndicated market report, published as Advanced Cancer Pain Management(ACPM) - Market Insights, Epidemiology and Market Forecast-2028. It is complete Research Study and Industry Analysis of Advanced Cancer Pain Management(ACPM) market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
